{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Leukemia%2C+Lymphocytic%2C+Chronic%2C+B+Cell&page=21", "query": { "condition": "Leukemia, Lymphocytic, Chronic, B Cell", "page": 21 }, "page_size": 10 }, "pagination": { "page": 21, "page_size": 10, "total_count": 1599, "total_pages": 160, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Leukemia%2C+Lymphocytic%2C+Chronic%2C+B+Cell&page=22&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Leukemia%2C+Lymphocytic%2C+Chronic%2C+B+Cell&page=20&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-14T14:33:14.988Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT07220187", "title": "Adding Pirtobrutinib to the Usual Treatment for People With Newly Diagnosed Richter Transformation, The PIRAMID Trial", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Richter Syndrome", "Transformed Chronic Lymphocytic Leukemia to Diffuse Large B-Cell Lymphoma", "Transformed Small Lymphocytic Lymphoma to Diffuse Large B-Cell Lymphoma" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Doxorubicin Hydrochloride", "type": "DRUG" }, { "name": "Echocardiography Test", "type": "PROCEDURE" }, { "name": "Multigated Acquisition Scan", "type": "PROCEDURE" }, { "name": "Pirtobrutinib", "type": "DRUG" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Rituximab", "type": "BIOLOGICAL" }, { "name": "Rituximab and Hyaluronidase Human", "type": "BIOLOGICAL" }, { "name": "Survey Administration", "type": "OTHER" }, { "name": "Vincristine", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL", "OTHER" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 102, "start_date": "2026-08-04", "completion_date": "2036-10", "has_results": false, "last_update_posted_date": "2026-10-13", "last_synced_at": "2026-10-14T14:33:14.988Z", "location_count": 62, "location_summary": "Irvine, California • Laguna Hills, California • Orange, California + 48 more", "locations": [ { "city": "Irvine", "state": "California" }, { "city": "Laguna Hills", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Bloomington", "state": "Illinois" }, { "city": "Canton", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT07220187" }, { "nct_id": "NCT01527838", "title": "Single Treatment With FT1050 of an Ex-vivo Modulated Umbilical Cord Blood Unit", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-Hodgkin's Lymphoma (NHL)", "Hodgkin's Disease", "Chronic Lymphocytic Leukemia (CLL)", "Acute Myelogenous Leukemia (AML)", "Acute Lymphoblastic Leukemia (ALL)" ], "interventions": [ { "name": "Single FT1050 treated UCB unit", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Fate Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 10, "start_date": "2012-01", "completion_date": "2013-11", "has_results": false, "last_update_posted_date": "2016-09-12", "last_synced_at": "2026-10-14T14:33:14.988Z", "location_count": 3, "location_summary": "Boston, Massachusetts • Columbus, Ohio", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT01527838" }, { "nct_id": "NCT00741455", "title": "Chemotherapy Followed by Allogeneic Stem Cell Transplantation for Hematologic Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Hematologic Malignancies" ], "interventions": [ { "name": "Stem Cell Transplant", "type": "PROCEDURE" }, { "name": "G-CSF", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "Cyclosporine", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "Dartmouth-Hitchcock Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 18, "start_date": "2004-06", "completion_date": "2020-05-01", "has_results": true, "last_update_posted_date": "2020-11-23", "last_synced_at": "2026-10-14T14:33:14.988Z", "location_count": 1, "location_summary": "Lebanon, New Hampshire", "locations": [ { "city": "Lebanon", "state": "New Hampshire" } ], "official_url": "https://clinicaltrials.gov/study/NCT00741455" }, { "nct_id": "NCT01732913", "title": "Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Indolent Non-Hodgkin's Lymphomas" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Idelalisib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 295, "start_date": "2013-01-16", "completion_date": "2016-05-18", "has_results": true, "last_update_posted_date": "2018-11-16", "last_synced_at": "2026-10-14T14:33:14.988Z", "location_count": 32, "location_summary": "Huntsville, Alabama • Chandler, Arizona • Duarte, California + 28 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Chandler", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Fullerton", "state": "California" }, { "city": "Long Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01732913" }, { "nct_id": "NCT01005979", "title": "A Phase I Trial Using Cyclophosphamide, Rituximab and Revlimid (CR2) for the Treatment of Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL) and Small Lymphocytic Lymphoma (SLL)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Leukemia, Lymphocytic, Chronic, B-Cell", "Chronic Lymphocytic Leukemia", "Lymphoma, Small Lymphocytic" ], "interventions": [ { "name": "Lenalidomide, Rituximab, and Cyclophosphamide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2010-07", "completion_date": null, "has_results": false, "last_update_posted_date": "2014-08-13", "last_synced_at": "2026-10-14T14:33:14.988Z", "location_count": 1, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01005979" }, { "nct_id": "NCT00001586", "title": "Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): DNA Microarray Gene Expression Analysis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Lymphocytic Leukemia" ], "interventions": [ { "name": "Rituximab", "type": "BIOLOGICAL" }, { "name": "Fludarabine phosphate", "type": "DRUG" }, { "name": "Leukemic or stroma cells", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 105, "start_date": "1997-09", "completion_date": "2011-11", "has_results": true, "last_update_posted_date": "2013-05-15", "last_synced_at": "2026-10-14T14:33:14.988Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00001586" }, { "nct_id": "NCT02037256", "title": "Bortezomib and Filgrastim to Promote Stem Cell Mobilization in Patients With Non-Hodgkin Lymphoma or Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Adult Grade III Lymphomatoid Granulomatosis", "B-cell Chronic Lymphocytic Leukemia", "Contiguous Stage II Adult Burkitt Lymphoma", "Contiguous Stage II Adult Diffuse Large Cell Lymphoma", "Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma", "Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma", "Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma", "Contiguous Stage II Adult Lymphoblastic Lymphoma", "Contiguous Stage II Grade 1 Follicular Lymphoma", "Contiguous Stage II Grade 2 Follicular Lymphoma", "Contiguous Stage II Grade 3 Follicular Lymphoma", "Contiguous Stage II Mantle Cell Lymphoma", "Contiguous Stage II Marginal Zone Lymphoma", "Contiguous Stage II Small Lymphocytic Lymphoma", "Cutaneous B-cell Non-Hodgkin Lymphoma", "Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue", "Intraocular Lymphoma", "Nodal Marginal Zone B-cell Lymphoma", "Noncontiguous Stage II Adult Burkitt Lymphoma", "Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma", "Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma", "Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma", "Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma", "Noncontiguous Stage II Adult Lymphoblastic Lymphoma", "Noncontiguous Stage II Grade 1 Follicular Lymphoma", "Noncontiguous Stage II Grade 2 Follicular Lymphoma", "Noncontiguous Stage II Grade 3 Follicular Lymphoma", "Noncontiguous Stage II Mantle Cell Lymphoma", "Noncontiguous Stage II Marginal Zone Lymphoma", "Noncontiguous Stage II Small Lymphocytic Lymphoma", "Progressive Hairy Cell Leukemia, Initial Treatment", "Recurrent Adult Burkitt Lymphoma", "Recurrent Adult Diffuse Large Cell Lymphoma", "Recurrent Adult Diffuse Mixed Cell Lymphoma", "Recurrent Adult Diffuse Small Cleaved Cell Lymphoma", "Recurrent Adult Grade III Lymphomatoid Granulomatosis", "Recurrent Adult Immunoblastic Large Cell Lymphoma", "Recurrent Adult Lymphoblastic Lymphoma", "Recurrent Grade 1 Follicular Lymphoma", "Recurrent Grade 2 Follicular Lymphoma", "Recurrent Grade 3 Follicular Lymphoma", "Recurrent Mantle Cell Lymphoma", "Recurrent Marginal Zone Lymphoma", "Recurrent Small Lymphocytic Lymphoma", "Refractory Hairy Cell Leukemia", "Refractory Multiple Myeloma", "Small Intestine Lymphoma", "Splenic Marginal Zone Lymphoma", "Stage I Adult Burkitt Lymphoma", "Stage I Adult Diffuse Large Cell Lymphoma", "Stage I Adult Diffuse Mixed Cell Lymphoma", "Stage I Adult Diffuse Small Cleaved Cell Lymphoma", "Stage I Adult Immunoblastic Large Cell Lymphoma", "Stage I Adult Lymphoblastic Lymphoma", "Stage I Grade 1 Follicular Lymphoma", "Stage I Grade 2 Follicular Lymphoma", "Stage I Grade 3 Follicular Lymphoma", "Stage I Mantle Cell Lymphoma", "Stage I Marginal Zone Lymphoma", "Stage I Multiple Myeloma", "Stage I Small Lymphocytic Lymphoma", "Stage II Multiple Myeloma", "Stage III Adult Burkitt Lymphoma", "Stage III Adult Diffuse Large Cell Lymphoma", "Stage III Adult Diffuse Mixed Cell Lymphoma", "Stage III Adult Diffuse Small Cleaved Cell Lymphoma", "Stage III Adult Immunoblastic Large Cell Lymphoma", "Stage III Adult Lymphoblastic Lymphoma", "Stage III Grade 1 Follicular Lymphoma", "Stage III Grade 2 Follicular Lymphoma", "Stage III Grade 3 Follicular Lymphoma", "Stage III Mantle Cell Lymphoma", "Stage III Marginal Zone Lymphoma", "Stage III Multiple Myeloma", "Stage III Small Lymphocytic Lymphoma", "Stage IV Adult Burkitt Lymphoma", "Stage IV Adult Diffuse Large Cell Lymphoma", "Stage IV Adult Diffuse Mixed Cell Lymphoma", "Stage IV Adult Diffuse Small Cleaved Cell Lymphoma", "Stage IV Adult Immunoblastic Large Cell Lymphoma", "Stage IV Adult Lymphoblastic Lymphoma", "Stage IV Grade 1 Follicular Lymphoma", "Stage IV Grade 2 Follicular Lymphoma", "Stage IV Grade 3 Follicular Lymphoma", "Stage IV Mantle Cell Lymphoma", "Stage IV Marginal Zone Lymphoma", "Stage IV Small Lymphocytic Lymphoma", "Untreated Hairy Cell Leukemia", "Waldenström Macroglobulinemia" ], "interventions": [ { "name": "bortezomib", "type": "DRUG" }, { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "autologous hematopoietic stem cell transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "PROCEDURE" ], "sponsor": "Barbara Ann Karmanos Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 23, "start_date": "2011-07", "completion_date": "2015-01-21", "has_results": true, "last_update_posted_date": "2021-05-10", "last_synced_at": "2026-10-14T14:33:14.988Z", "location_count": 1, "location_summary": "Detroit, Michigan", "locations": [ { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT02037256" }, { "nct_id": "NCT01527045", "title": "Donor Atorvastatin Treatment in Preventing Severe Acute GVHD After Nonmyeloablative Peripheral Blood Stem Cell Transplant in Patients With Hematological Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Aggressive Non-Hodgkin Lymphoma", "Blasts Under 5 Percent of Bone Marrow Nucleated Cells", "Chronic Lymphocytic Leukemia", "Loss of Chromosome 17p", "Myelodysplastic/Myeloproliferative Neoplasm", "Non-Hodgkin Lymphoma", "Prolymphocytic Leukemia", "Recurrent Adult Acute Lymphoblastic Leukemia", "Recurrent Adult Acute Myeloid Leukemia", "Recurrent Aggressive Adult Non-Hodgkin Lymphoma", "Recurrent Childhood Acute Lymphoblastic Leukemia", "Recurrent Childhood Acute Myeloid Leukemia", "Recurrent Chronic Lymphocytic Leukemia", "Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "Recurrent Diffuse Large B-Cell Lymphoma", "Recurrent Hodgkin Lymphoma", "Recurrent Mantle Cell Lymphoma", "Recurrent Non-Hodgkin Lymphoma", "Recurrent Plasma Cell Myeloma", "Recurrent Small Lymphocytic Lymphoma", "Waldenstrom Macroglobulinemia" ], "interventions": [ { "name": "Atorvastatin Calcium", "type": "DRUG" }, { "name": "Cyclosporine", "type": "DRUG" }, { "name": "Fludarabine Phosphate", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Mycophenolate Mofetil", "type": "DRUG" }, { "name": "Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Peripheral Blood Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Total-Body Irradiation", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "OTHER", "PROCEDURE", "RADIATION" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 47, "start_date": "2012-09-25", "completion_date": "2019-04", "has_results": true, "last_update_posted_date": "2020-01-02", "last_synced_at": "2026-10-14T14:33:14.988Z", "location_count": 2, "location_summary": "Denver, Colorado • Seattle, Washington", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT01527045" }, { "nct_id": "NCT01087294", "title": "Administration of Anti-CD19-chimeric-antigen-receptor-transduced T Cells From the Original Transplant Donor to Patients With Recurrent or Persistent B-cell Malignancies After Allogeneic Stem Cell Transplantation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Leukemia, B-cell", "Lymphoma, Hodgkins", "Lymphoma, Non-hodgkins", "Lymphoma, B-Cell" ], "interventions": [ { "name": "Allogeneic stem cell transplant", "type": "PROCEDURE" }, { "name": "Anti-CD19-chimeric-antigen-receptor-transduced T cells", "type": "BIOLOGICAL" }, { "name": "Leukapheresis", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 85, "start_date": "2010-08-04", "completion_date": "2024-04-02", "has_results": false, "last_update_posted_date": "2026-10-13", "last_synced_at": "2026-10-14T14:33:14.988Z", "location_count": 2, "location_summary": "Bethesda, Maryland • Minneapolis, Minnesota", "locations": [ { "city": "Bethesda", "state": "Maryland" }, { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT01087294" }, { "nct_id": "NCT00005641", "title": "Removal of T Cells to Prevent Graft-Versus-Host Disease in Patients Undergoing Bone Marrow Transplantation", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Myeloproliferative Disorders", "Graft Versus Host Disease", "Leukemia", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic Syndromes" ], "interventions": [ { "name": "anti-thymocyte globulin", "type": "BIOLOGICAL" }, { "name": "busulfan", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "cyclosporine", "type": "DRUG" }, { "name": "leucovorin calcium", "type": "DRUG" }, { "name": "methotrexate", "type": "DRUG" }, { "name": "methylprednisolone", "type": "DRUG" }, { "name": "allogeneic bone marrow transplantation", "type": "PROCEDURE" }, { "name": "in vitro-treated bone marrow transplantation", "type": "PROCEDURE" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "15 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "15 Years to 60 Years" }, "enrollment_count": null, "start_date": "1997-09", "completion_date": "2000-09", "has_results": false, "last_update_posted_date": "2012-12-11", "last_synced_at": "2026-10-14T14:33:14.988Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00005641" } ] }